Valuation: Appili Therapeutics Inc.

Market Cap 1.32M 940K 826K 768K 704K 90.51M 1.34M 9.12M 3.56M 44.5M 3.53M 3.45M 154M P/E 2025
-1.62x
P/E 2026 -0.44x
Enterprise Value 14.22M 10.1M 8.87M 8.25M 7.57M 972M 14.44M 97.94M 38.26M 478M 37.91M 37.09M 1.65B EV / Sales 2025
152,429,607x
EV / Sales 2026 60,946,081x
Free-Float
99.94%
Yield 2025 *
-
Yield 2026 -
07-04 Appili Therapeutics Inc. Receives Notice of Termination for Convenience from National Institute of Allergy and Infectious Diseases on Contract for VXV-01 Program CI
06-27 Appili Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 CI
06-27 Appili Therapeutics Inc. Auditor Raises 'Going Concern' Doubt CI
02-18 Appili Therapeutics announces closing of second tranche of non-brokered private placement RE
02-13 Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
12-18 Appili Therapeutics closes first tranche of non-brokered private placement RE
12-15 The Lundquist Institute and Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID CI
11-14 Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
11-14 Appili Therapeutics Brief: On LIKMEZ (ATI-1501), Says "Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth" MT
11-14 Appili Therapeutics Brief: Citing New NIAID Non-Dilutive Funding Award of Up to US $40 Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs MT
11-14 Appili Therapeutics Brief: Reported a Q2 Net and Comprehensive Loss of $1.0 million ($0.01 per share) MT
11-05 Appili Therapeutics Announces $750,000 Private Placement for Working Capital, Drug Development MT
11-05 Appili Therapeutics announces proposed non-brokered private placement RE
1 day-33.33%
1 week-33.33%
Current month-33.33%
1 month-33.33%
3 months-33.33%
6 months-50.00%
Current year-60.00%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.02
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.08
5 years 0.01
Extreme 0.01
1.14
10 years 0.01
Extreme 0.01
1.89
Manager TitleAgeSince
Chief Executive Officer 65 01/11/2022
Director of Finance/CFO 68 16/11/2021
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 50 07/05/2015
Director/Board Member 58 01/10/2018
Chairman 59 13/11/2022
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Option

Chief Executive Officer

75,000 0.0584%
01/07/26 Option

Chief Financial Officer

100,000 0.0779%
01/07/26 Option

Director

100,000 0.0779%
Change 5-day change 1-year change 3-year change Capi.($)
-33.33%-33.33%-33.33%-81.82% 940K
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -4.27%+1.15%+32.84%+142.28% 24.01B
Weighted average by Cap. -0.87%+2.10%+39.70%+133.49%

Financials

2025 2026
Net sales 0.1 0.07 0.06 0.06 0.05 6.87 0.1 0.69 0.27 3.38 0.27 0.26 11.68 0.24 0.17 0.15 0.14 0.13 16.7 0.25 1.68 0.66 8.21 0.65 0.64 28.38
Net income -2.62M -1.86M -1.64M -1.52M -1.4M -179M -2.67M -18.08M -7.06M -88.24M -7M -6.85M -305M -4.24M -3.01M -2.64M -2.46M -2.26M -290M -4.31M -29.21M -11.41M -143M -11.3M -11.06M -493M
Net Debt 11.07M 7.86M 6.9M 6.42M 5.89M 757M 11.24M 76.22M 29.78M 372M 29.5M 28.86M 1.29B 12.9M 9.16M 8.04M 7.48M 6.86M 882M 13.1M 88.82M 34.7M 434M 34.38M 33.64M 1.5B
Logo Appili Therapeutics Inc.
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Employees
7
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. APLI Stock